Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anna Svarna
Observed names:
A. Svarna,
Anna SVARNA
Institutions:
National and Kapodistrian University of Athens,
Alexandra Hospital
Observed institutions:
National and Kapodistrian University of Athens,
Alexandra Hospital
ORCID:
0000-0002-7897-0272
Observed ORCID:
0000-0002-7897-0272
OpenAlex ID:
A5039101986
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
2024
·
Angeliki Andrikopoulou
, Flora Zagouri
, et al.
·
BMC Cancer
·
19
PDF
Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives
2025
·
Nikolaos Dedes
, Michalis Liontos
, et al.
·
Biomedicines
·
11
PDF
BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
2021
·
Michalis Liontos
, Eleni Zografos
, et al.
·
Current Oncology
·
7
PDF
What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literature
2023
·
Anna Svarna
, Michalis Liontos
, et al.
·
Gynecologic Oncology Reports
·
5
Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review
2025
·
Anna Svarna
, Michalis Liontos
, et al.
·
Current Oncology
·
4
PDF
Possible Prognostic Role of BMI Before Chemotherapy in the Outcomes of Women with Ovarian Cancer
2025
·
Stavroula A. Paschou
, Angeliki Andrikopoulou
, et al.
·
Nutrients
·
4
PDF
Prognostic and predictive significance of CA-125 elimination rate constant K (KELIM) in ovarian cancer patients treated with neoadjuvant chemotherapy in a real-world setting.
2023
·
Michael Liontos
, Alkistis Papatheodoridi
, et al.
·
Journal of Clinical Oncology
·
4
PDF
Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor Expression
2026
·
Anna Svarna
, Michalis Liontos
, et al.
·
Current Oncology
·
1
PDF
Real world data of maintenance treatment in homologous recombination (HR)–proficient HGSOC.
2025
·
Angeliki Andrikopoulou
, Anna Svarna
, et al.
·
Journal of Clinical Oncology
·
1
Immunohistochemical expression of ER and p53 as predictive biomarkers of immunotherapy in endometrial cancer.
2023
·
Michael Liontos
, Aristea-Maria Papanota
, et al.
·
Journal of Clinical Oncology
·
1
PDF
77P The impact of COVID-19 on gynecological cancer diagnoses in Greece
2023
·
O. Fiste
, P. Iliopoulou
, et al.
·
ESMO Open
·
1
PDF
Paraneoplastic pemphigus associated with squamous cell carcinoma of the cervix
2022
·
O. Fiste
, M. Liontos
, et al.
·
Forum of Clinical Oncology
·
1
PDF
What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience
2021
·
Michalis Liontos
, Anna Svarna
, et al.
·
Current Oncology
·
1
PDF
Molecular testing for prostate cancer patients in Greece
2026
·
Michalis LIONTOS
, Elena KUNADIS
, et al.
·
Hellenic Urology
157P Determinants of long-term disease-free survival in advanced ovarian cancer: A real-world analysis
2026
·
A. Svarna
, M. Liontos
, et al.
·
ESMO Open
PDF
189eP No survival benefit from interval debulking surgery in elderly patients with advanced ovarian cancer: Evidence from real-world practice
2026
·
M. Liontos
, A. Svarna
, et al.
·
ESMO Open
PDF
146P Dynamic folate receptor-α (FRα) expression in recurrent ovarian cancer patients undergoing secondary debulking surgery: A real-world analysis
2026
·
M. Liontos
, T. Papadopoulou
, et al.
·
ESMO Open
PDF
Efficacy of chemotherapy after PARP inhibitor progression in ovarian cancer: A large real-world cohort.
2026
·
Michael Liontos
, Theodora Papadopoulou
, et al.
·
Journal of Clinical Oncology
Real-world outcomes of first-line enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
2026
·
Anna Svarna
, Michael Liontos
, et al.
·
Journal of Clinical Oncology
Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in recurrent platinum-resistant ovarian cancer: A real-world study.
2026
·
Angeliki Andrikopoulou
, Michael Liontos
, et al.
·
Journal of Clinical Oncology
1197P Limited clinical benefit of chemotherapy in ovarian cancer patients progressing during or after PARPi maintenance treatment
2025
·
K.C. Aravantinou Fatorou
, M. Liontos
, et al.
·
Annals of Oncology
2524eP Real-world treatment patterns, efficacy and survival outcomes in men with mCRPC in Greece: The ProsThera study
2025
·
M. Tsiatas
, M. Liontos
, et al.
·
Annals of Oncology
PDF
106P Clinicopathological characteristics and long-term clinical outcomes of early-stage ovarian cancer patients: A single institution experience
2025
·
M. Liontos
, N.G. Dedes
, et al.
·
ESMO Open
PDF
91P Increased BMI is associated with improved survival in advanced ovarian cancer patients receiving maintenance treatment with bevacizumab
2025
·
M. Liontos
, A. Andrikopoulou
, et al.
·
ESMO Open
PDF
107P Clinicopathological characteristics and long-term probability for disease recurrence in advanced ovarian cancer patients: A single-institution analysis
2025
·
M. Liontos
, A. Svarna
, et al.
·
ESMO Open
PDF
Show more works
View as search
Works count:
32
Citation count:
60
H-index:
4
I10-index:
2
Year
Topic
Type